Sartorius Stedim: posts strong profitable growth
(CercleFinance.com) - The life science research and biopharmaceutical group's 9m sales rose 29.
2% to 1,379.4 million euros: order intake increased by 43.9% to 1,637.9 million euros.
Underlying EBITDA increased by 39.2% to 434.7 million euros, meaning a margin that is up from 29.0% to 31.5% year-on-year.
Net income, group share increased by 40.4% compared to sales, reaching 278.1 million euros. Consolidated EPS amounted to 3.02 euros (vs. 2.15 euros the previous year).
Its FY 2020 underlying EBITDA margin is now estimated at 32% (vs. 31% previously). Management maintains its targets, including sales of approximately 2.8 billion euros and an underlying EBITDA margin of almost 30% by 2025.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
2% to 1,379.4 million euros: order intake increased by 43.9% to 1,637.9 million euros.
Underlying EBITDA increased by 39.2% to 434.7 million euros, meaning a margin that is up from 29.0% to 31.5% year-on-year.
Net income, group share increased by 40.4% compared to sales, reaching 278.1 million euros. Consolidated EPS amounted to 3.02 euros (vs. 2.15 euros the previous year).
Its FY 2020 underlying EBITDA margin is now estimated at 32% (vs. 31% previously). Management maintains its targets, including sales of approximately 2.8 billion euros and an underlying EBITDA margin of almost 30% by 2025.
Copyright (c) 2020 CercleFinance.com. All rights reserved.